News Releases

Month Year

Email Alerts

May 23, 2018

VFMCRP and CARA Therapeutics to develop and commercialise CR845 injection for Chronic kidney disease-associated pruritu

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) to develop and commercialise CR845/difelikefalin injection worldwide except in the US, Japan and South Korea for the treatment of chronic kidney...
May 15, 2018

90th Vifor Pharma Group Annual Shareholder Meeting

All proposals of the Board of Directors approved by shareholders Election of Jacques Theurillat to the Board of Directors Re-election of standing members of the Board of Directors Dividend of CHF...
Mar 29, 2018

Vifor Pharma to propose to Jacqules Theurillat as board member

Jacques Theurillat to be proposed to Annual Shareholder Meeting for appointment to Board Marc de Garidel will not stand for re-election All other members of the Board of Directors will stand for...
Mar 17, 2018

Vifor Pharma concludes licensing agreement with Zeria to Market VELTASSA® in Japan

Vifor Pharma gives Zeria exclusive rights to develop and market Veltassa® in Japan Potential of Veltassa® further validated with expansion into Japanese market Deal expands cardio-renal network...
Mar 15, 2018

Vifor Pharma Group reports strong 2017 results, exceeding raised guidence

IN 2017 VIFOR PHARMA RECORDED A STRONG FINANCIAL PERFORMANCE DRIVEN BY ITS THREE MEDIUM-TERM STRATEGIC GROWTH-DRIVERS AND THE SUCCESSFUL DIVESTITURE OF ITS NON-CORE WHOLESALE/RETAIL PHARMACY...
Mar 8, 2018

US FDA Approves use of VELTASSA® with or without food

Updated label may allow for increased dosing flexibility for patients with hyperkalaemia Label update effective immediately in the US THE UNITED STATES (US) FOOD AND DRUG ADMINISTRATION (FDA) HAS...
Feb 8, 2018

Vifor Pharma ferroportin inhibitor enters Phase-I clinical trial

VIFOR PHARMA ANNOUNCED TODAY THAT VIT-2763, THE FIRST-EVER ORAL FERROPORTIN INHIBITOR FOR PREVENTING IRON OVERLOAD WILL ENTER CLINICAL DEVELOPMENT WITH A PHASE-I STUDY AT THE BEGINNING OF MARCH...
Jan 4, 2018

Avacopan conditional marketing authorization application accepted for regulatory review by European Medicines Agency

Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney...
Jan 4, 2018

Veltassa® approved for marketing in Switzerland for the treatment of Hyperkalaemia

Klicken Sie hier für Deutsch Veuillez cliquer ici pour français SWISSMEDIC HAS APPROVED PATIROMER TO BE MARKETED IN SWITZERLAND AS VELTASSA® FOR THE TREATMENT OF HYPERKALAEMIA (ELEVATED SERUM...
Nov 23, 2017

Third Global Iron Deficiency Day to Raise Awareness of the Symptoms of Iron Deficiency

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Sep 27, 2017

Vifor Pharma Expands Exclusive License Agreement for the Commercialisation of Mircera® in the Us

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Aug 8, 2017

Vifor Pharma Reports Strong H1 2017 Results and Raises Guidance

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jul 21, 2017

European Commission Approves Marketing Authorisation for Veltassa®

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jul 18, 2017

New Expert Review in the American Journal of Hematology Seeks to Change the Way We Test, Treat and Talk About Iron Deficiency in Chronic Inflammatory Conditions

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jul 12, 2017

Vifor Pharma Announces Three Outcomes Trials in Heart Failure and Iron Deficiency

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jun 9, 2017

Kissei to Market Avacopan in Japan for Vifor Fresenius Medical Care Renal Pharma

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 19, 2017

Chmp Recommends Veltassa® for the Treatment of Hyperkalaemia in the Eu

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 16, 2017

Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.s. Upon Fda Approval

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 11, 2017

89th Annual General Meeting of Galenica Ltd.

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Apr 12, 2017

Galenica Santé Ipo – Full Exercise of Over-allotment Option

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Apr 7, 2017

Successful Galenica Santé Ipo, Galenica Group Becomes Vifor Pharma Group

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Apr 3, 2017

Ipo Galenica Santé: Galenica Announces Narrowed Price Range and Upsizing of the Ipo

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Mar 24, 2017

Advance Information Ipo of Galenica Santé

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Mar 24, 2017

Galenica Launches Ipo of Galenica Santé and Sets Price Range

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Mar 21, 2017

COMCO Ruling Against Hci Solutions Ltd.

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Mar 14, 2017

Galenica Announces Plans for Ipo of Galenica Santé on Six Swiss Exchange

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Mar 14, 2017

Board of Directors Launches “milestone 2020” Strategy Plan: Galenica Group to Become Vifor Pharma Group and Float Galenica Santé on the Stock Exchange

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Mar 14, 2017

Results of the Galenica Group 2016

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Feb 22, 2017

Galenica Santé Adds Merfen® and Vita-merfen® to Its Otc Product Portfolio

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Feb 20, 2017

Vifor Pharma Continues Commitment to Raise Awareness of Iron Deficiency

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Feb 14, 2017

Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jan 19, 2017

Planned Division of the Galenica Group

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jan 19, 2017

2016 Sales of the Galenica Group

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jan 11, 2017

The Galenica Group is Taking Over Sd Wholesaler Pharmapool

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jan 9, 2017

Change to the Shareholder Structure of the Galenica Group

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Dec 23, 2016

Vifor Pharma and Chemocentryx Announce Expansion of Kidney Health Alliance

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Dec 23, 2016

Vifor Pharma and ChemoCentryx announce expansion of Kidney Health Alliance to include CCX140 to treat renal diseases

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Dec 9, 2016

Swisscom Health to take over Galenica practice information system

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Dec 7, 2016

EFFECT-HF demonstrates a significantly beneficial effect of Ferinject® on exercise capacity among patients with chronic heart failure and iron deficiency – confirms findings of previous studies

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Nov 28, 2016

FDA Approves Supplemental New Drug Application for Veltassa® Removing Boxed Warning Regarding Drug-Drug Interactions

PDF VERSION OF PRESS RELEASE Back to overview of Press Release
Nov 24, 2016

Vifor Pharma leads initiatives to raise awareness of Iron Deficiency – 2nd Global Iron Deficiency Day on November 26, 2016

PDF VERSION OF PRESS RELEASE Back to overview of Press Release
Oct 25, 2016

Swissmedic approves ALOXI® for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Children in Switzerland

PDF VERSION OF PRESS RELEASE Back to overview of Press Release
Oct 6, 2016

Appointments at the Galenica Group: New management at Vifor Pharma and new Galenica Group CFO designated

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Sep 2, 2016

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma’s position in cardio-renal therapies

PDF VERSION OF PRESS RELEASE Back to overview of Press Release
Sep 1, 2016

Galenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Aug 9, 2016

Galenica reports double-digit profit growth in the first half of 2016

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Aug 4, 2016

Galenica commences Tender Offer for Relypsa

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jul 21, 2016

Galenica and Relypsa announce agreement for Galenica to acquire Relypsa. Acquisition strengthens Galenica’s Business unit, Vifor Pharma – an important step towards becoming an independent specialty pharma company

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 24, 2016

Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer’s proposed epoetin alfa biosimilar, Retacrit™, in the US dialysis market

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 24, 2016

Vifor Pharma to further strengthen company management to ensure continued strong growth.

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 23, 2016

The 2016 ESC heart failure guidelines strongly recommend Ferinject® for the treatment of iron deficiency in patients with systolic heart failure

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 11, 2016

Change to the shareholder structure of the Galenica Group

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 10, 2016

Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s OrallyAdministered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 10, 2016

Vifor Pharma appoints Colin Bond as Chief Financial Officer

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 9, 2016

Vifor Fresenius Medical Care Renal Pharma and OPKO Health enter into Agreement for OPKO’s RAYALDEE

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Apr 28, 2016

88th Annual General Meeting of Galenica Ltd.: Shareholders approve all proposals submitted by the Board of Directors

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Apr 25, 2016

Vifor Fresenius Medical Care Renal Pharma submits marketing authorisation application requesting European approval of Patiromer for treatment of hyperkalemia

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Mar 15, 2016

Galenica 2015: profit increased for the 20th consecutive year

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jan 21, 2016

Galenica in 2015: strong sales growth and confirmation of the 20th consecutive increase in profit

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases

Show per page

Filter by Company: